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PI3K/AKT activation induces PTEN ubiquitination
and destabilization accelerating tumourigenesis
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The activity of the phosphatase and tensin homologue (PTEN) is known to be suppressed via
post-translational modiﬁcation. However, the mechanism and physiological signiﬁcance by
which post-translational modiﬁcations lead to PTEN suppression remain unclear. Here we
demonstrate that PTEN destabilization is induced by EGFR- or oncogenic PI3K mutation-
mediated AKT activation in cervical cancer. EGFR/PI3K/AKT-mediated ubiquitination and
degradation of PTEN are dependent on the MKRN1 E3 ligase. These processes require the
stabilization of MKRN1 via AKT-mediated phosphorylation. In cervical cancer patients with
high levels of pAKT and MKRN1 expression, PTEN protein levels are low and correlate with a
low 5-year survival rate. Taken together, our results demonstrate that PI3K/AKT signals
enforce positive-feedback regulation by suppressing PTEN function.
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A
potent inhibitor of the PI3K/AKT pathway is PTEN
(phosphatase and tensin homologue), a tumour suppres-
sor that is highly mutated or deleted in various human
cancers1–4. PTEN plays a pivotal role in tumour cell growth
and migration5–7. The germline mutation of PTEN in several
inherited cancer syndromes such as Cowden syndrome,
Bannayan–Zonana syndrome and Lhermitte–Duclos disease
supports the importance of PTEN as a tumour suppressor8–10.
Although somatic mutation or genetic deletion of PTEN in
cervical cancers has been reported previously, a tumour-
suppressing role of PTEN in cervical carcinoma has yet
to be identiﬁed11. Functionally, the lipid phosphatase
PTEN antagonizes the PI3K–AKT signalling pathway by
catalysing phosphatidylinositol-3,4,5-trisphosphate (PIP3) to
phosphatidylinositol-4,5-bisphosphate (PIP2)6. Thus, PTEN
exhibits tumour-suppressing abilities by inactivating down-
stream oncogenic AKT-mediated signalling. In addition to
genetic alterations of PTEN in human cancers, various post-
translational modiﬁcations (PTMs) of PTEN have been actively
investigated, including phosphorylation, ubiquitination,
acetylation and oxidation; these PTMs control the ability of
PTEN to inhibit PI3K/AKT signalling7,12–14. Frequent genetic
aberrations of PTEN in human cancer, including depletion of the
PTEN protein, are observed in only 25% of cancers15, suggesting
that PTMs may be important in PTEN function. The recent
discovery of several E3 ligases and deubiquitinases such as
NEDD4-1, WWP2, XIAP, CHIP, SPOP, USP7 (HAUSP) and
USP13 seems to imply that PTEN stability and subcellular
localization are important in cancer development14,16–21.
However, the physiological context of PTEN stability has yet to
be addressed.
MKRN1 has been identiﬁed as an oncogenic E3 ligase that
induces the degradation of p53, p21, p14ARF and FADD
activities22–25. While MKRN1 has been proposed to function
as an inhibitor of tumour suppressors, the upstream path-
ways regulating MKRN1 function have yet to be identiﬁed.
Here, we demonstrate that a growth factor-activated PI3K/AKT
pathway suppresses PTEN via MKRN1-mediated ubiquitination
and degradation. The positive relationship between these post-
translational regulatory pathways and clinical evidence is
conﬁrmed by analysis of samples from cervical cancer
patients. Supporting these observations, xenografts and
biochemical analyses indicate inverse correlations between
PTEN and the PI3K/AKT-activated MKRN1 axis. These
ﬁndings suggest a pathway for PI3K/AKT signalling in the
regulation of PTEN.
Results
AKT signalling is suppressed following depletion of MKRN1.
MKRN1 is a potential oncogene, based on its ability to
degrade several tumour suppressors, including p53 and p21
(refs 22–24). In support of these observations, MKRN1 is
overexpressed in human cervical and breast carcinomas24. To
further deﬁne the oncogenic properties of MKRN1, the signalling
pathways of various kinases in MKRN1-depleted HeLa cells
were screened using dot blots of 34 antibodies against speciﬁc
kinases. Intriguingly, MKRN1 depletion was associated with
the suppression of pAKT, pmTOR and p-p70 S6K, which are
critical components of PI3K/AKT-mediated oncogenic signalling
pathways (Fig. 1a). Furthermore, a decrease in the levels of
pAKT or its downstream phosphoproteins, including p70 S6K
and GSK3b, was detected in both MKRN1 / mouse embryonic
ﬁbroblasts (MEFs) and HeLa cells depleted of MKRN1 by
RNAi #6 or #7 (Fig. 1b,c). For controls, p53 and p14ARF as
targets of MKRN1 are detected here (Fig. 1b,c)23,25. The in vitro
phosphorylation analysis of AKT in the absence of MKRN 1
further conﬁrms that MKRN1 depletion induces AKT
inactivation (Fig. 1d). Because PTEN is the crucial antagonist of
the PI3K/AKT proto-oncogenic axis, we also analysed PTEN
levels in MKRN1-depleted MEFs or HeLa cells. MKRN1 ablation
induced an increase in PTEN protein expression but did not have
a substantial effect on PTEN messenger RNA levels, suggesting a
potential role of MKRN1 in the post-translational regulation of
PTEN (Fig. 1b,c,e). The simultaneous down- and upregulation of
AKT and PTEN, respectively, by MKRN1 ablation led us to
examine whether the inhibition of AKT signalling by MKRN1
elimination is dependent on an increase in PTEN. The ablation of
PTEN completely reversed the effect of MKRN1 knockdown on
pAKT expression and that of its downstream effectors (Fig. 1f).
Compellingly, PTEN depletion induced the activation of AKT
and also led to an increase in MKRN1, suggesting that active
pAKT might affect MKRN1 (Fig. 1f, lane 4). Collectively, MKRN1
depletion appears to induce PTEN stabilization, consequently
leading to the deactivation of AKT signalling pathways. By
contrast, PTEN depletion led to the activation of AKT and an
increase in MKRN1, suggesting an association among pAKT,
MKRN1 and PTEN.
MKRN1 overexpression correlates with tumour progression.
On the basis of the results presented in Fig. 1, the clinical
implications of AKT, MKRN1 and PTEN levels were pursued.
First, to determine the clinical relevance of MKRN1 expression in
human cancer, we used immunohistochemistry (IHC) to com-
pare MKRN1 expression levels in human cervical tissue from
patients with cervical intraepithelial neoplasia (CIN) or invasive
cervical carcinoma. The clinicopathological characteristics of the
study are summarized in Supplementary Table 1. The expression
of MKRN1 was increased in CIN and tumours compared with
normal cells (Po0.001, one-way analysis of variance (ANOVA)
and independent t-test) (Fig. 2a,b; Supplementary Fig. 1). The
expression of pAKT and pmTOR was also higher in CIN and
tumours than in normal cells, whereas the expression of PTEN
was decreased in CIN and tumour tissue compared with normal
cells, suggesting a link between MKRN1 and the PI3K/AKT
pathway (Fig. 2; Supplementary Table 2). Furthermore, MKRN1
immunoreactivity was signiﬁcantly correlated with advanced
disease and poor outcome, including the FIGO stage (P¼ 0.018,
one-way ANOVA and independent t-test) and tumour
grade (Po0.001, one-way ANOVA and independent t-test).
Similar results were obtained for pAKT expression (Fig. 2b;
Supplementary Table 1). By contrast, the expression of PTEN was
upregulated in normal specimens compared with cancer and
high-grade CIN (Po0.001, one-way ANOVA and independent
t-test, Fig. 2b). Notably, in all cervical cancer and CIN specimens,
the expression of MKRN1 was positively correlated with the
expression of pAKT (Spearman’s rho¼ 0.167 (P¼ 0.030) and
Spearman’s rho¼ 0.411 (Po0.001), respectively), whereas
MKRN1 expression was negatively correlated with PTEN
expression (Spearman’s rho¼  0.260 (P¼ 0.001) and Spear-
man’s rho¼  0.175 (P¼ 0.002), respectively, Supplementary
Table 2). In addition, after further deﬁned analysis in the
CIN subgroups, the LGCIN group did not show statistically
meaningful negative correlation (Spearman’s rho¼  0.020,
P¼ 0.861), HGCIN (Spearman’s rho¼  0.133, P¼ 0.045) and
Cancer (Spearman’s rho¼  0.175, P¼ 0.002) group showed a
strong negative correlation between MKRN1 and PTEN. The
discrepancy between LGCIN and HGCIN/Cancer resulted from
pathophysiological characteristics, because human papilloma
virus (HPV) replication in LGCIN is without cell proliferation,
whereas in HGCIN, cell proliferation occurs, resulting in the
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progression towards cervical cancer (Supplementary Table 2). We
next examined the relationship between MKRN1 expression and
patient survival. Kaplan–Meier plots demonstrated that patients
with high MKRN1 expression had signiﬁcantly worse overall
survival (mean of 47.6 versus 59.5 months, log-rank test
Po0.001; Fig. 2c). Furthermore, patients with a combination of
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Figure 1 | Depletion of MKRN1 suppresses the AKTsignalling pathway. (a) Alteration of cellular signalling in an MKRN-abrogated cervical cell line. HeLa
cells were transduced with 20 nM control siRNA (siControl) or MKRN1 siRNA #7 (siMKRN1) and harvested 48 h post transfection. The diluted lysates
were analysed using a human phosphokinase array kit (R&D Systems, ARY003). The mean values (n¼ 2 in each blot) of phosphoproteins quantiﬁed
relative to control siRNA-transfected cells (siControl) were divided into three groups (blue: activated signal, red: inactivated signal and grey: unaltered
signal). (b,c) MKRN1 depletion suppresses the AKT signalling pathway and elevates PTEN expression. Wild-type (WT) or MKRN1 knockout (MKRN1 KO)
mouse embryonic ﬁbroblasts (MEFs) were analysed by immunoblotting at passage 5. RNAi knockdown was performed in HeLa cells with two independent
siRNAs for MKRN1 (siMKRN1 #6 and siMKRN1 #7). (d) MKRN1 RNAi inhibits AKT activity in vitro. In vitro AKT kinase assay were performed using AKT
puriﬁed from siControl or siMKRN1-transfected HeLa cells. Error bars indicate s.d. n¼ 3. (e) MKRN1 RNAi had no effect on the mRNA level of PTEN. Total
RNA was puriﬁed from siControl or the two types of siMKRN1-transfected HeLa cells, and mRNA levels of MKRN1 and PTEN were validated by real-time
PCR analysis (data shown as mean±s.d.; n¼ 3). (f) MKRN1 knockdown inhibits AKT signalling in a PTEN-dependent manner. HeLa cells were transduced
with RNAi for MKRN1 #7 or PTEN as indicated. Cells were lysed and analysed by immunoblotting.
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high MKRN1 and high pAKT expression or high MKRN1 and
low PTEN expression had signiﬁcantly worse overall survival
(mean of 46.5 versus 59.8 months, log-rank test Po0.001, and
mean of 46.9 versus 59.5 months, log-rank test Po0.001,
respectively) than patients who had low MKRN1 and low pAKT
expression or low MKRN1 and high PTEN expression (Fig. 2c;
Supplementary Fig. 2). The Cox proportional hazards model
revealed that high MKRN1 expression (hazard ratio¼ 4.11 (95%
conﬁdence interval (CI), 1.12–15.03), P¼ 0.033), a combination
of high MKRN1 and high pAKT (hazard ratio¼ 5.94 (95% CI,
2.08–16.93), P¼ 0.001) or high MKRN1 and low PTEN (hazard
ratio¼ 4.59 (95% CI, 1.64–12.80), P¼ 0.004) expression were
independent prognostic factors with respect to overall survival
(Fig. 2d). Taken together, these data indicate that MKRN1
expression is an important prognostic factor in human cervical
cancer, possibly due to its role in modulating a PTEN-dependent
AKT inhibition pathway.
AKT activation suppresses PTEN by MKRN1 stabilization. The
cellular and clinical data implicating potential associations among
AKT, MKRN1 and PTEN led us to hypothesize that the PI3K/
AKT signalling pathway might exert negative regulatory effects
on PTEN stabilization, possibly via MKRN1. Mechanistically, the
PI3K/AKT axis leading to PTEN deregulation is unknown, but it
has been suggested that PIP3 participates in the regulation of
PTEN ubiquitination and stability26,27. To unravel the possible
connection among AKT, MKRN1 and PTEN, AKT was activated
via epidermal growth factor (EGF) treatment following serum
starvation of ME-180 cervical cancer cells. AKT immediately
attained its activated pAKT state following EGF treatment, as
previously reported (Fig. 3a). Intriguingly, MKRN1 levels
increased at 18 h after EGF treatment, simultaneous with a
decrease in PTEN protein expression. There was no apparent
change in the messenger RNA level of either protein, suggesting
that these events depend on post-translational processes
(Fig. 3a,b). The MKRN1 stabilization and PTEN destabilization
induced by EGF treatment were inhibited by either treatment
with LY294002 (a PI3K inhibitor) and MK-2206 (an allosteric
AKT inhibitor) or AKT knockdown (Fig. 3c,d). In contrast,
treatment with PD98059 or AZD6244, MEK inhibitors, did not
have much effect on EGF-mediated phosphorylation of pAKT,
MKRN1 stabilization or PTEN destabilization, suggesting that the
EGF–MAPK pathway might not be involved in these processes
(Supplementary Fig. 3b). Note that MEK inhibitors suppressed
EGF-induced ERK phosphorylation within 30min. Furthermore,
ERK pathway was inhibited at 8 h after EGF treatment by the
negative-feedback loop previously reported (Supplementary
Fig. 3a,b). These observations imply that EGF-driven PI3K/
AKT activation might be related to the protein stabilities of
MKRN1 and PTEN. Results similar to those shown for ME-180
were also observed in other cell lines, including H1299, HepG2
and Hep3B cells and MEFs, indicating that EGF-driven regulation
of MKRN1 and PTEN is not only restricted in cervical cancer cell
lines (Supplementary Fig. 3c). Furthermore, the inhibition of
EGF-mediated PTEN destabilization upon MKRN1 ablation
indicates that MKRN1 might have a regulatory effect on
PTEN stabilization (Fig. 3d). To further elucidate the regulatory
role of EGF in the interaction among AKT, MKRN1 and
PTEN, the effects of PI3K on MKRN1 and PTEN levels were
investigated. As previously reported, the stable overexpression
of the constitutively active PI3K mutants PIK3CA p110a
E545K or H1047R induced pAKT and pGSK3b, with
simultaneous stabilization of MKRN1 and destabilization of
PTEN (Fig. 3e)28,29. By contrast, MKRN1 ablation suppressed
PI3K-dependent pAKT activation but stabilized PTEN (Fig. 3f).
Collectively, these results suggest that the PI3K/AKT axis may
induce concurrent post-translational stabilization of MKRN1 and
destabilization of PTEN.
AKT stabilizes MKRN1 through phosphorylation. Given that
EGF stabilizes the MKRN1 protein, possibly via activation of the
PI3K/AKT axis, we investigated whether MKRN1 is a substrate
for AKT. Employing co-immunoprecipitation assays using
endogenous, overexpressed or recombinant proteins, an interac-
tion between AKT1 and MKRN1 was detected (Fig. 4a–d). A
search for a potential MKRN1 phosphorylation site revealed a
consensus AKT phosphorylation motif including serine 109 of
MKRN1 (Fig. 4e). Although the motif (RXRXXXS), including
serine 109 of MKRN1, is only a partial AKT consensus motif
(RXRXXS/T), an AKT substrate containing an RXRXXXS motif
has been reported. Furthermore, previous structural studies have
indicated that the RXRXXXS motif is a highly plausible AKT-
targeting sequence30,31. To determine whether AKT targets the
serine 109 site of MKRN1 for phosphorylation, we substituted
alanine at this site. A subsequent in vitro phosphorylation assay
using32 P-labelled adenosine triphosphate (ATP) and puriﬁed
GST-AKT under cell-free conditions revealed that wild-type
(WT) MKRN1 was phosphorylated, but not an S109A mutant
(Fig. 4f). In accordance with this ﬁnding, only Myr-AKT (the
active form of AKT) but not K179M (a kinase-dead form of AKT)
was able to induce phosphorylation of WT MKRN1 but not the
S109A mutant (Fig. 4g). Upon EGF treatment, an anti-
phosphoserine antibody speciﬁcally detected pMKRN1, and
MKRN1 was stabilized (Fig. 4h). Depletion or inhibition of
AKT by short interfering RNA (siRNA) suppressed EGF-driven
MKRN1 phosphorylation (Fig. 4i). Finally, phospho-AKT
substrate antibody detecting phosphorylation on the over-
expressed MKRN1 but not on the S109A mutant by Myr-AKT1
further suggests that the serine 109 site of MKRN1 is speciﬁcally
phosphorylated by AKT (Supplementary Fig. 4). These data
suggest that MKRN1 might be post-translationally stabilized via
AKT-mediated phosphorylation.
Figure 2 | Determining protein expression in human cervical neoplasia specimens. The tissue microarray (TMA) contains 190 cases of cervical cancer.
However, due to the complexity of sectioning and staining and sample heterogeneity, only 169, 181, 165 and 181 of the 190 samples could be interpreted for
MKRN1, pAKT, pmTOR and PTEN expression, respectively. (a) Representative images of immunohistochemical staining of MKRN1, pAKT, pmTOR and
PTEN in normal, low-grade CIN, high-grade CIN and invasive cervical cancer tissues. The boxed regions are displayed at high magniﬁcation in the inset.
Scale bars, 200mm. (b) Box plot depiction of IHC scores. IHC staining scores for MKRN1 and pAKTwere signiﬁcantly higher in cervical cancer samples than
in low-grade CIN and normal controls. By contrast, the IHC score for PTEN was signiﬁcantly lower in cancer samples than in CIN and normal controls.
Error bars represent mean±s.d. IHC scores were compared by one-way ANOVA and an independent t-test. (*po0.01 and **po0.001). (c) Kaplan–Meier
plots indicate the overall survival for cervical cancer patients categorized by tumour stage, LN metastasis, or MKRN1, pAKT, pmTOR or PTEN expression.
(d) Univariate and multivariate analyses of the associations between prognostic variables and overall survival in cervical cancer. MKRN1þ , histoscoreZ8;
pAKTþ , histoscore Z8; pmTORþ , histoscore Z3; PTEN-, histoscore o1; LN metastasis, lymph node metastasis. Data were analysed using a one-way
ANOVA and an independent t-test.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8769 ARTICLE
NATURE COMMUNICATIONS | 6:7769 | DOI: 10.1038/ncomms8769 | www.nature.com/naturecommunications 5
& 2015 Macmillan Publishers Limited. All rights reserved.
To further demonstrate the link between the AKT-mediated
phosphorylation and stabilization of MKRN1, the effects of
constitutively active Myr-AKT or inactive AKT (K179M) on
MKRN1 were analysed. As expected, Myr-AKT increased
MKRN1 protein levels, while K179M did not (Fig. 5a). Cyclo-
heximide (CHX) treatment indicated that Myr-AKT expression
or EGF treatment prolongs the half-lives of endogenous MKRN1,
conﬁrming that active AKT stabilizes MKRN1 (Fig. 5b,c).
Treatment of cells with the proteasome inhibitors MG132 and
LLnL resulted in the full recovery of basal MKRN levels to that
mediated by Myr-AKT, demonstrating that MKRN1 is constantly
destabilized via the proteasomal degradation pathway (Fig. 5d).
On the basis of these observations, the ubiquitinated forms of
MKRN1 were measured in response to EGF treatment. The
results indicated that the ubiquitinated MKRN1 forms disap-
peared upon EGF treatment (Fig. 5e; Supplementary Fig. 5). By
contrast, the ablation of AKT restored ubiquitinated MKRN1,
indicating that the inhibition of MKRN1 ubiquitination is
dependent on EGF-mediated AKT activation (Fig. 5e). We next
examined whether AKT-mediated MKRN1 phosphorylation
affects the ubiquitination process, because phosphorylation
stabilizes MKRN1 proteins. We generated a phosphorylated
MKRN1 mimetic named S109D in which serine 109 was replaced
with an aspartate to mimic the effects of phosphorylation on the
charge of serine 109. As expected, the S109D mutant was fully
protected against destabilization by CHX treatment and exhibited
decreased levels of ubiquitination compared with WT (Fig. 5f,g).
In summary, the PI3K/AKT-mediated phosphorylation of
MKRN1 hinders its ubiquitination, ultimately stabilizing the
MKRN1 protein.
MKRN1 functions as a PTEN E3 ubiquitin ligase. Our results
provided several clues suggesting that MKRN1 is an E3 ubiquitin
ligase for PTEN, including the results presented in Fig. 1. Figure 1
shows that MKRN1 depletion increased PTEN protein levels
(Fig. 1b,c), while cells in which the PI3K/AKT/MKRN1 pathway
was stimulated by EGF exhibited an MKRN1-dependent decrease
in PTEN protein levels and (Fig. 3d). On the basis of these data,
the potential role of MKRN1 as an E3 ligase for PTEN was
investigated. First, co-immunoprecipitation analysis using over-
expressed, endogenous and recombinant MKRN and PTEN
revealed that MKRN1 binds to PTEN (Supplementary Fig. 6a–d).
Domain mapping analysis suggested that the C terminus of
MKRN1 is responsible for its interaction with PTEN
(Supplementary Fig. 4e). The overexpression of MKRN1 in
H1299 cells induced a decrease in endogenous, as well as exo-
genous, PTEN protein levels (Fig. 6a). The half-life of endogenous
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PTEN was also decreased by MKRN1 overexpression (Fig. 6b).
On the other hand, the half-life of endogenous PTEN increased
following MKRN1 depletion in cells treated with CHX (Fig. 6c).
Ubiquitination assays performed under protein-denaturing
conditions demonstrated that the ubiquitinated forms of exo-
genous PTEN were enhanced by the overexpression of MKRN1
but not the enzymatically defective H307E MKRN1 mutant
(Fig. 6d; Supplementary Figs 7c and 8a). These ﬁndings
support the data demonstrating that the overexpression of WT
MKRN1, but not the H307E mutant, shortened the half-life of the
exogenous PTEN protein (Supplementary Fig. 7a,b). In vitro
ubiquitination assays conducted using either recombinant or
cellular proteins demonstrated that MKRN1 directly facilitated
the PTEN ubiquitination process (Fig. 6e; Supplementary
Fig. 8b,c). To investigate the physiological implications of
PTEN destabilization, the effect of MKRN1 or AKT depletion on
the ubiquitination status of endogenous PTEN was examined.
PTEN ubiquitination was sharply diminished by the ablation
of either MKRN1 or AKT, suggesting that both MKRN1 and
AKT are involved in PTEN ubiquitination processes (Fig. 6f).
In addition, MKRN1 was shown to predominantly induce
K48-linked polyubiquitination of PTEN (Supplementary Fig. 8d).
Collectively, these analyses indicate that the stabilization of the
MKRN1 E3 ligase by pAKT-mediated phosphorylation leads to
PTEN ubiquitination and degradation, and that MKRN1 is a
novel E3 ligase for PTEN.
The active PI3K/AKT signal destabilizes PTEN. The ability of
the EGF/PI3K/AKT axis to activate MKRN1, which might con-
sequently induce PTEN destabilization, led us to investigate
whether this signalling pathway could affect the ubiquitination
status of PTEN. The ubiquitination of endogenous PTEN was
considerably increased 24 h after EGF treatment, with simulta-
neous activation of the pAKT/MKRN1 axis (Fig. 7a). Notably,
PTEN ubiquitination decreased upon AKT or MKRN1 ablation,
indicating that EGF-driven PTEN ubiquitination is pAKT- and
MKRN1 dependent (Fig. 7b,c). Consistent with these observa-
tions, overexpression of Myr-AKT induced the endogenously
ubiquitinated PTEN, which was suppressed in the absence of
MKRN1 (Supplementary Fig. 9). The ubiquitination and sub-
sequent degradation of PTEN are mediated by several E3 ligases,
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including NEDD4-1 and WWP2 (refs 16,17). Thus, we examined
whether other PTEN E3 ligases were involved in PTEN regulation
similar to MKRN1. Consistent with the ﬁndings of previous
studies, knockdown of either NEDD4-1 or WWP2 induced PTEN
stabilization in ME-180 cells (Fig. 7d). siNEDD4-1 #3 and
siWWP2 #5, which increased PTEN levels, were then used to
determine whether NEDD and WWP2 are involved in PTEN
regulation through EGF-mediated signalling pathways. Upon
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EGF exposure, only MKRN1 depletion fully interfered with the
active EGF/PI3K/AKT axis-mediated ubiquitination of PTEN,
whereas neither NEDD4-1 nor WWP2 had this effect (Fig. 7e). In
addition, the known ubiquitination sites, K13 and K289, on
PTEN by NEDD4 were tested for MKRN1’s targeting. The results
showed that MKRN1 could speciﬁcally target K289 but not K13
for ubiquitination. Supporting these data, MKRN1 could not
mediate the degradation of K289R, implying that MKRN1 and
NEDD4 have a common target site on PTEN (Supplementary
Fig. 8e,f). Taken together, these results indicate that the EGFR/
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PI3K/AKT signal suppresses PTEN stability and activity through
MKRN1-mediated ubiquitination and degradation.
MKRN1 regulates the tumorigenicity of cervical cancer. Several
studies have demonstrated that PTEN-mediated tumour growth
and inhibition of metastasis are related to the suppression of the
PI3K/AKT pathway5. To determine the oncogenic effects of
MKRN1-mediated inhibition of the PTEN tumour suppressor
and activation of the PI3K/AKT pathway, we conducted a
transwell migration assay using human cervical cancer cell lines
(HeLa, ME-180 and CaSki). The migration abilities of MKRN1-
depleted cells were strongly reduced (Supplementary Fig. 10, left
panel). The number of migratory cells was reduced too20% that
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in the control upon treatment with the individual MKRN1 RNAis
(Supplementary Fig. 10, right panel). As expected, the inhibition
of cell migration by MKRN1 depletion was reversed in PTEN-
ablated cells (Fig. 8a). To conﬁrm the effects of MKRN1 on
cancer cell proliferation and motility, additional wound-healing
assays were performed. To obtain live wound-healing images,
RNA interference (RNAi)-transfected cells were injured, and
IncuCyte was applied for further detection and analyses.
Consistent with the transwell migration data, MKRN1-depleted
cells exhibited an apparent reduction in migration rate compared
with controls. This reduction was rescued by simultaneous PTEN
ablation (Fig. 8b).
To investigate the inverse correlation between MKRN1 and
PTEN in cervical cancer cell lines, in vivo xenograft analyses were
performed. ME-180 cells from which MKRN1 had been stably
eliminated were subcutaneously transplanted into athymic nude
mice (Fig. 8c). The injected tumours that contained a retroviral-
based MKRN1 short hairpin RNA (shRNA) vector exhibited
distinct growth retardation compared with control shRNA
vector-infected tumours. Notably, the concomitant stable
depletion of PTEN completely reversed the tumour growth
inhibition achieved by MKRN1 knockdown (Fig. 8c–e). The same
phenomena were observed with cell lines tested in vitro
(Supplementary Fig. 11a). Examination of the AKT signal in
the tumour lysates revealed that MKRN1 knockdown diminished
pAKT in a PTEN-dependent manner, in agreement with our
previous observations (Supplementary Fig. 11b). Because MKRN1
could also target p53 or p14ARF, we further tested whether
these factors might have some effects in the reverse correlation
between MKRN1 and PTEN. For these, we employed HCT116
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Figure 8 | Loss of MKRN1 suppresses cervical cancer cell mobility and growth. (a) The migratory properties of siMKRN1 #7- and siPTEN-transfected
cervical cancer cell lines (HeLa, ME-180 and CaSki) were analysed by a migration assay using a collagen-coated Transwell chamber. The photographic
images represent haematoxylin and eosin-stained migratory cells (left panel, magniﬁcation:  200, scale bar, 50mm). Migratory cells were plotted as the
average number of cells per ﬁeld of view in three different experiments (right panel, data are shown as the mean±s.d. ***Po0.001, based on the Student’s
t-test.). (b) The scratch assay was performed using siMKRN1 #7- and siPTEN-transduced cervical cancer cell lines (HeLa, ME-180 and CaSki). The wound-
healing images were analysed every 1 h or 30min using the IncuCyte live-cell imaging system; the graph shows the percentages of sealing conﬂuence as
deﬁned by the IncuCyte software (error bars represent mean±s.d.; n¼ 3). (c–e) Representative images of tumours and mice at day 38 after the
subcutaneous injection of 2 106 ME-180 cells stably expressing shGFP or MKRN1 shRNA (shMK1 #2 or shMK1 #5) or PTEN shRNA (shPTEN) (c). Bars,
1 cm. Tumour growth is shown in the graph (d), and tumour mass is described at day 38 after implantation (e). The data shown in d and e are the
mean±s.d.; n¼ 6 mice per group in c–e. *Po0.05, **Po0.01 and ***Po0.001, based on the Student’s t-test.
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and ME-180, a colorectal and cervical cancer cell line,
respectively. By using HCT116 p53 / , we could remove p53
as well as p14ARF, which is ectopically suppressed in HCT116
cells32. Because ME-180 contains E6, which suppresses p53, stable
knockdown of p14ARF enabled us to exclude the effects of both
proteins. In these cells, the suppression of MKRN1 induced
growth retardation, which was reversed by the knockdown of
PTEN (Supplementary Fig. 12). Furthermore, using ME-180
stably transfected with ARF shRNA, we performed xenograft
analysis in the absence of MKRN1 or MKRN1 and PTEN. The
data showed that the deleterious effects of MKRN1 depletion on
cells could be rescued by PTEN depletion alone in the
xenografted tumours derived from the cervical cancer cell line
(Supplementary Fig. 13). Notably, while the depletion of p53
relieved some of the tumour-suppressive effects upon MKRN1
ablation (Supplementary Fig. 12a), HCT116 still required
depletion of PTEN for full growth recovery of cancer cells.
Taken together, these results suggest that the loss of MKRN1
inhibits cervical cancer tumorigenesis through active PTEN
stabilization.
Discussion
PTEN is a major tumour suppressor that antagonizes growth
factor-stimulated PI3K/AKT signalling by converting PIP3 to
PIP2. PTEN loss of function is linked to various sporadic human
cancers, including endometrial, glioblastoma, melanoma, lung,
breast and prostate, with an average mutational frequency rate of
B25% (refs 15,33,34). The frequent loss of heterozygosity in
human cancers, the inverse correlation between PTEN dosage and
tumorigenicity in a mouse model and the variety of PTEN
regulatory mechanisms, including microRNA targeting and
protein stability, suggest that variations in PTEN levels in cells
might affect tumour progression5,12,34. Among those ﬁndings, the
recent identiﬁcation of the post-translational regulation of
PTEN by phosphorylation, oxidation, acetylation, ubiquitination/
deubiquitination and so on has generated widespread speculation
on the implications of PTEN protein stability in tumorigenic
processes7,12,33. While biochemical studies have investigated the
post-translational regulation of PTEN associated with clinical
behaviour, the detailed regulatory mechanisms of PTEN in a
physiological context are not yet understood.
In this study, we identiﬁed a novel negative regulatory
mechanism of PTEN involving EGF-dependent PI3K/AKT
activation. Because PTEN’s potent tumour-suppressing activities
largely stem from its inhibitory effects on AKT activation, cells,
whether normal or cancerous, must ﬁnd ways to suppress PTEN
during the active stimulation of cellular proliferation by cell
growth signalling. Evidence indicating that growth factor
signalling pathways post-translationally eliminate the inhibitory
effects of PTEN has been limited. The increase in PTEN
ubiquitination upon EGF stimulation but not in the absence of
AKT or MKRN1 suggests the presence of coordinated pathways
between the EGFR/AKT/MKRN axis and PTEN (Fig. 7). In fact,
EGF-stimulated pAKT phosphorylates and subsequently stabi-
lizes MKRN1, which then ubiquitinates and induces the
degradation of PTEN. The stabilization of MKRN1 by EGF-
mediated AKT activation with concomitant PTEN degradation
suggests that a positive-feedback pathway activates AKT (Fig. 1f;
Fig. 3). MKRN1 appears to be the only E3 ligase associated with
the EGF-activated AKT pathway (Fig. 7).
Although persistent infection with high-risk HPV is a major
factor for the development of cervical carcinomas, high-risk HPV
alone is not sufﬁcient to induce tumour progression35. Less than
4% of HPV-infected individuals acquire premalignant lesions or
develop tumours, suggesting a role for host factors associated
with HPV11,36. Recent genome-wide association studies (GWAS)
and DNA sequencing data on human cervical cancer have
revealed that candidate host factors with somatic mutations
include MAPK1, RAS, ERBB2, PTEN and PIK3CA11,37. Among
these proteins, mutations in ERBB2, RAS and PIK3CA may result
in the constitutive activation of AKT. Active AKT could then
stimulate its downstream effectors, such as MKRN1, leading to
the suppression of PTEN; this mechanism may be reﬂected in the
IHC and survival data in Fig. 2. While the above-indicated
relationships between AKT and its downstream factors require
further analyses in cervical cancer patients, our observations are
sufﬁciently consistent with GWAS of cervical carcinomas to
postulate that PTMs of AKT, MKRN1 and PTEN play important
roles in coordinating the development of malignant cancers.
Furthermore, the detection of a non-functional PTEN mutant in
GWAS of cervical cancers implies that the impairment of PTEN-
related pathways might be involved in the development of
cervical cancer11. Our novel ﬁndings regarding the EGF/PI3K/
AKT/MKRN1 axis leading to PTEN suppression, along with
previous data on mutations in ERBB2, and PIK3CA, ultimately
indicate that ERBB2- or PIK3CA-targeted drugs might be
potential therapeutic treatments for cervical cancers.
Methods
Cell culture and transfection. HeLa, ME-180 and CaSki cells (human cervical
cancer cell lines) were procured from the Korean Cell Line Bank (KCLB, Seoul,
Korea) and cultured in RPMI supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Thermo Scientiﬁc). H1299 (a human lung carcinoma cell
line), HEK293T (a human embryonic kidney cell line) and MKRN1þ /þ or
MKRN1 / MEFs25 were cultured in DMEM with 10% fetal bovine serum and
1% penicillin/streptomycin (Thermo Scientiﬁc). H1299 and HEK293T were
purchased from the American Type Culture Collection (ATCC, Manassas, VA).
The ATCC and KCLB authenticate the phenotypes of these cell lines on a regular
basis. All cell lines were maintained in 5% CO2 at 37 C. Plasmid DNA was
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), and siRNA
was transfected using Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s protocol. For EGF stimulation, cells were starved overnight in
medium supplemented with 0.2% serum, followed by treatment with EGF
(100 ngml 1; Sigma-Aldrich, St Louis, MO).
Plasmids. The MKRN1 open-reading frame (ORF)-containing plasmids
pcDNA3.1-MKRN1 WT/H307E, pcDNA3-HA-MKRN1 WT/H307E, pcDNA3-
FLAG-MKRN1 WT/H307E and pGEX-4T-1-GST-MKRN1 WT/H307E were
described previously23. MKRN1 S109A/S109D plasmids were generated by site-
directed mutagenesis and subcloned into a pcDNA3-FLAG vector. The full-length
PTEN ORF was kindly provided by Han-Woong Lee (Yonsei University) and
subcloned into pcDNA3-HA or pcDNA3-FLAG. The AKT1 ORF-containing
plasmids pLNCX-Myr-HA-Akt1-WT and K179M were purchased from Addgene
(Cambridge, MA, USA), and the AKT1 ORF was subcloned into pcDNA3.1.
The PIK3CA ORF-containing plasmids pBabe-puro-HA-PIK3CA E545K and
H1047R were purchased from Addgene. pcDNA3-His-Ub was kindly provided
by D.P. Lane38. pHM6-HA-Ub has been described previously39. pEGFP-C2
(Clontech, San Diego, CA) was used as a transfection control.
Antibodies and chemicals. The following antibodies were used: PTEN (1:1,000,
Santa Cruz, SC-7974 mouse, clone A2B1; or 1:1,000, Cell Signaling, 9559 rabbit),
MKRN1 (1:1,000, Bethyl Laboratories, A300-990A), NEDD4-1 (1:1,000, Cell Sig-
naling, 3607), WWP2 (1:1,000, Bethyl Laboratories, A302-936A), pAKT (Ser473,
1:2,000, Cell Signaling, 9271; T308, 1:2,000, Cell Signaling, 4056), AKT1 (1:2,000,
Cell Signaling, 2967 mouse, clone 2H10), AKT1/2 (1:2,000, Santa Cruz, SC-8312
rabbit), p-p70 S6 kinase (Thr389, 1:2,000, Cell Signaling, 9205), p70 S6 kinase
(1:2,000, Cell Signaling, 2708), pGSK3b (Ser9, 1:3,000, Cell Signaling, 9323),
GSK3b (1:3,000, Cell Signaling, 9315), pERK1/2 (Thr202/Tyr204, 1:3,000, Cell
Signaling, 4370), ERK1/2 (1:3,000, Cell Signaling, 4695), phosho-AKT substrate
(RXRXXpS/pT, Cell Signaling, 10001), horseradish peroxidase (HRP)-conjugated-
a-Ub FK2 (1:2,000, Biomol, PW0150), phosphoserine (Sigma, P5747), hae-
magglutinin (HA) (1:1,000, Santa Cruz, sc-7392 mouse; 1:1,000, Santa Cruz, sc-805
rabbit; or 1:2,000, Roche, 12013819001, clone 3F10), FLAG (1:5,000, Sigma, F3165
mouse; or 1:2,000, Sigma, F7425 rabbit), GST (1:1,000, Santa Cruz, sc-138), green
ﬂuorescent protein (GFP) (1:2000, Santa Cruz, sc-8334) and b-actin (1:5,000,
Sigma, A5316). Human EGF (E9644), LY294002 (L9908), LLnL (A6185) and CHX
(C4859) were purchased from Sigma-Aldrich. PD98059 (153000) and MG132 were
purchased from Calbiochem (San Diego, CA). MK-2206 (S1078) and AZD6244
(S1008) were purchased from Selleck Chemicals.
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Protein assays. WT and H307E GST-MKRN1 were puriﬁed from bacteria using
GST Sepharose beads according to the manufacturer’s protocol (GE Healthcare).
Recombinant GST-AKT1 protein (Biomol International, SE-416) and recombinant
His-PTEN (Calbiochem, 481409) were purchased. In vitro translated IVT-HA-
AKT1 and IVT-FLAG-PTEN proteins were obtained using a TNT T7-coupled
reticulocyte lysate system (Promega, L4610). FLAG-MKRN1 WT/S109A and
FLAG-PTEN proteins were puriﬁed using ANTI-FLAG M2 Afﬁnity Gel (Sigma,
A2220) and FLAG peptide (Sigma, F3290) from HEK293T cells expressing FLAG-
tagged proteins. To conﬁrm their interaction in vitro, GST-tagged proteins were
incubated with in vitro translated proteins for 2 h, followed by the addition of GST
Sepharose beads and incubation for 1 h. Finally, the beads were washed and eluted
in 10mM reduced glutathione. To perform the immunoprecipitation assay, cells
were lysed in lysis buffer (50mM Tris-HCl (pH 7.5), 150mM NaCl, 0.5% Triton
X-100 and 1mM EDTA) containing a protease inhibitor cocktail. The cell lysates
were then incubated with 1 mg of antibody for 2 h with gentle rotation, followed by
incubation with 25 ml of protein G agarose (Invitrogen) for 2 h. The beads were
washed three times with lysis buffer free of protease inhibitors, and the precipitated
proteins were eluted in SDS sample buffer under boiling conditions. Full blots are
shown in Supplementary Fig. 14
In vivo and in vitro ubiquitination assay. The in vivo ubiquitination assay was
conducted under denaturing conditions. Brieﬂy, to detect proteins ubiquitinated by
His-conjugated ubiquitin, cells were lysed in 6M guanidinium-HCl buffer (pH 8)
containing 5mM N-ethylmaleimide (NEM, Sigma-Aldrich) to prevent deubiqui-
tination. Using Ni2þ -NTA beads (Qiagen, Valencia, CA), His-ubiquitin-con-
jugated proteins were pulled down and washed. To detect proteins ubiquitinated
with HA-conjugated-ubiquitin or endogenously ubiquitinated proteins under
denaturing conditions, cells were lysed by boiling for 10min in PBS containing 1%
SDS and 5mM NEM. The lysates were immunoprecipitated in lysis buffer (a ﬁnal
concentration of 0.1% SDS). For immunoblotting, proteins were transferred to
polyvinylidene diﬂuoride membranes and denatured using 6M guanidine-HCl
containing 20mM Tris-HCl (pH 7.5), 5mM mercaptoethanol and 1mM phe-
nylmethyl sulphonyl ﬂuoride for 30min at 4 C. Ubiquitinated proteins were
identiﬁed by HRP-conjugated anti-Ub antibodies (FK2, PW0150, Biomol). In vitro
ubiquitination assays were performed by combining 0.5 mg of the bacterially pro-
duced recombinant proteins (GST-MKRN1 or His-PTEN) or 10 ml of the puriﬁed
proteins (FLAG-MKRN1 or FLAG-PTEN) from HEK293T cells with 100 ng of E1
(UBE1, E-305, Boston Biochem, Cambridge, MA, USA), 250 ng of E2 (UbcH5c,
E2-627, Boston Biochem) and 5 mg of ubiquitin (U-100H, Boston Biochem) in 20 ml
of reaction buffer (40mM Tris, 50mM NaCl, 5mM MgCl2, 2mM ATP, 1mM
dithiothreitol, pH 7.6) as indicated. The reaction was stopped after 3 h at 37 C by
the addition of SDS sample buffer and boiling.
Virus production and infection. Stable PIK3CA-expressing cell lines were
developed using retroviral expression vectors (pBabe-puro-HA-PIK3CA H1047R
or pBabe-puro-HA-PIK3CA E545K). HEK293T cells were transfected with
pBABE-puro together with VSV-G and a gag-pol-expressing vector followed by
incubation for 48 h to produce packaged retroviruses. Finally, to select for retro-
virus-infected cells, cell lines were incubated in 2 mgml 1 puromycin (Sigma-
Aldrich). Lentivirus-containing supernatant was collected 48 h after co-transfection
of the pLKO.1 shRNA-expressing vector and packaging vectors into HEK293T
cells, and added to ME-180 cells. After 48 h, infected cells were selected by treat-
ment with 2 mgml 1 puromycin. The following MISSION lentiviral shRNA
expression vectors for human MKRN1, human PTEN and control GFP were
purchased from Sigma-Aldrich: shMKRN1 #2 (TRCN0000041205, 50-CCGGCCA
GAGGTCACAGCACATAAACTCGAGTTTATGTGCTGTGACCTCTGGTTT
TTG-30), shMKRN1 #5 (TRCN0000 324883, 50-CGGGTGTTGGATCACTTGCT
GAAACTCGAGTTTCAGCAAGTGATCCAACACTTTTTG-30) and shPTEN #5
(TRCN0000230370, 50-CCGG CCACAAATGA AGGGATATAAACTCGAGTTT
ATATCCCTTCATTTGTGGTTTTTG-30).
In vivo and in vitro phosphorylation assays. To detect ectopically expressed or
endogenous phosphorylated MKRN1, EGF-stimulated cells were lysed in lysis
buffer containing a 1:100 dilution of phosphatase inhibitor cocktail (p5726,
Sigma-Aldrich). The lysates were immunoprecipitated overnight with 1 mg of anti-
phosphoserine; 25ml of protein G agarose beads was then added and incubated for
an additional 2 h. The beads were washed three times with lysis buffer, and the
precipitated proteins were eluted in SDS sample buffer under boiling conditions.
Phosphorylated MKRN1 was detected by immunoblotting with an anti-MKRN1
antibody. To detect phosphorylated MKRN1 in vitro, FLAG-MKRN1 WT/S109A
proteins (10 ml) were puriﬁed from HEK293T cells that were serum starved (0.2%
serum) for 24 h and incubated with recombinant active GST-AKT1 protein (1 mg,
Biomol International, SE-416) and 2 mCi of [g-32P]ATP in 50ml of 1 kinase
buffer (25mM Tris-HCl pH 7.5, 5mM b-glycerophosphate, 2mM dithiothreitol,
0.1mM Na3VO4, 10mM MgCl2 and 2 mM unlabelled ATP) for 1 h at 30 C.
Reactions were stopped by boiling in SDS sample buffer, and proteins were
resolved by 8% SDS–polyacrylamide gel electrophoresis. 32P incorporation was
detected by autoradiography.
siRNA sequences. All siRNAs were obtained from Qiagen and were resynthe-
sized: MKRN1 #6 (50-(CG)GGATCCTCTCCAACTGCAA-30), MKRN1 #7
(50-(CA)CAGGCGAAGCTGAGTCAAG-30), PTEN (50-ATCGATAGCATTTGC
AGTATA-30), AKT1 (50-(AA)TCACACCACCTGACCAAGA-30), NEDD4-1
(50-(AG)CCTACAATCTCTTATTAAA-30) and WWP2 (50-(AA)GCGGATGCTC
AATAAGAGA-30).
Reverse transcription–PCR analysis. Total RNA was prepared using TRIzol
reagent (Invitrogen), and complementary DNA was ampliﬁed using 1 mg of total
RNA and analysed using the QuantiTect SYBR Green PCR Kit and real-time
PCR (Rotor-GeneQ 2plex, Qiagen) with custom Primetime qPCR Primers (IDT,
Coralville, IA, USA): human MKRN1, 50-GAGAAGGACATGGAGCTCTCA-30
(forward) and 50-CGCCTTGTTGCTCATTGCCTC-30 (reverse); human PTEN,
50-GATGAGGCATTATCCTGTACACA-30 (forward) and 50-CTCTTCAGATAC
TCTTGTGCTGT-30 (reverse); and human glyceraldehyde-3-phosphate
dehydrogenase, 50-TGTAGTTGAGGTCAATGAAGGG-30 (forward) and 50-ACA
TCGCTCAGACACCATG-30 (reverse).
Human tumour samples. Cervical cancer tissue microarrays constructed by the
Korea Gynecologic Cancer Bank included 190 cervical cancers, 316 high-grade
CINs and 95 low-grade CINs. Primary tumour specimens were collected from 1996
to 2010. Patient consent was obtained. This study was approved by the institutional
review board of the Gangnam Severance Hospital, Yonsei University College of
Medicine (Supplementary Table 1).
Immunohistochemistry and scoring. Immunohistochemical staining was
performed as described previously40. MKRN1, pAKT, pmTOR and PTEN staining
results were scored based on (a) intensity (categorized as 0 (absent), 1 (weak),
2 (moderate) or 3 (strong)) and (b) the percentage of positively stained epithelial
cells (scored as 0 (0% positive), 1 (1–25%), 2 (26–50%), 3 (51–75%) or 4 (475%)).
A histoscore was generated by multiplying the intensity and positivity scores
(overall score range, 0–12). The immunohistochemical cutoff for high expression of
tumour markers was determined through receiver-operating characteristic curve
analysis41. Slides were scored without knowledge of any clinical information, and
the ﬁnal staining score was the average of scores from two independent pathologists.
Human phosphokinase array. Diluted lysates from siControl or siMKRN1
#7-transfected HeLa cells were incubated with human phosphokinase array
membranes (R&D Systems, ARY003), and bound phosphoproteins were analysed
according to the kit instructions. Each membrane contained kinase-speciﬁc and
positive control antibodies spotted in duplicate. The relative phosphorylation
of each spot was quantiﬁed by normalizing the pixel density to that of each
positive control. Values were expressed as the mean intensity of the siMKRN1
#7 membrane relative to the mean intensity of the siControl membrane.
Transwell migration and scratch wound healing. For the transwell migration
experiment, human cervical cancer cell lines (HeLa, ME-180 and CaSki) were
transfected with siMKRN1 #7 and siPTEN for 24 h, trypsinized, resuspended in
serum-free medium and added to the upper chambers of pore inserts of a transwell
with collagen type l (BD Bioscience)-coated ﬁlters. RPMI with 10% FBS and 1%
antibiotics (Thermo Scientiﬁc) were added to the lower chamber and incubated for
24 h. Migrating cells were quantiﬁed after haematoxylin and eosin staining. Each
experiment was performed in triplicate.
Human cervical cancer cell lines (HeLa, ME-180 and CaSki) transduced with
siMKRN1 #7 and siPTEN were plated and incubated for 24 h, until conﬂuence. A
wound was scratched across each well (Wound Maker, Essen BioScience, MI,
USA), and the wells were then rinsed with fresh medium to remove ﬂoating cells.
The wound-healing process was continuously monitored using the IncuCyte
live-cell imaging system (Essen BioScience). Wound healing was determined as a
percentage of wound conﬂuence.
In vivo tumorigenesis study. All animal studies involving the use of nude mice
were approved by the Animal Care and Use Committee of Yonsei University
Medical School (2013-0339), and were performed in speciﬁc pathogen-free
facilities in accordance with the Guidelines for the Care and Use of Laboratory
Animals of YUMS. ME-180 cells (2 106) stably expressing shRNA in 100 ml PBS
(mixed with Matrigel (BD Sciences) at a 1:1 ratio) were injected subcutaneously
into the ﬂanks of 6-week-old female-speciﬁc pathogen-free Balb/c nude mice
(Central Lab, Animal Inc., Korea) under anaesthesia. After the formation of
palpable tumours, tumour size was measured every 3 or 4 days using calipers, and
tumour volume was calculated according to the formula lengthwidth2 0.5236.
Mice were euthanized in a 7.5%-CO2 chamber when they met the institutional
euthanasia criteria for tumour size and overall health. The tumours were harvested,
photographed, weighed and subjected to other analyses.
Statistical analysis. Statistical analyses were performed using SPSS version 18.0
(SPSS Inc., Chicago, IL). Unless stated otherwise, all data are presented as the
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mean±s.d. IHC scores were compared by one-way ANOVA and an independent
t-test. Spearman’s rank correlation analysis was used to evaluate the associations
between pAKT, pmTOR, PTEN and MKRN1 expression. Survival curves were
estimated by the Kaplan–Meier analysis, and survival curves between groups were
compared using the log-rank test. Multivariate analysis was performed using the
Cox proportional hazards model to identify independent predictors of survival
after adjustment by relevant clinical covariates. A value of Po0.05 was considered
statistically signiﬁcant. The signiﬁcance of differences between groups was also
validated by one-way ANOVA and the unpaired two-tailed t-test using Prism
(version 7.0; GraphPad).
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